Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa

Phyllis Ocran, Zaheer-Ud-Din Babar, Fatima Suleman

Research output: Contribution to journalArticlepeer-review

Abstract

Background
Prices of cancer medicines are a major contributor to the cost of treatment for cancer patients and the comparison of these cost needs to be assessed.

Objectives
To assess the prices of cancer medicines for the three most common cancers ((breast, prostate and colorectal) in the private healthcare sector of South Africa.

Methods
The methodology was adapted from the World Health Organization (WHO)/ Health Action International (HAI) methodology for measuring medicine prices. The Single Exit Price (SEP) variations between product types of the same medicine between the highest- and lowest-priced product and between Originator Brand (OB) and its Lowest Priced Generic (LPG) of the same medicine brand was compared, as of March 2020. The affordability of those medicines for cancer usage based on treatment affordability in relation to the daily wage of the unskilled Lowest-Paid Government Worker (LPGW) was also determined. Also, a comparison of the proportion of the population below the poverty line (PL) before (Ipre) and after (Ipost) procurement of the cancer medicines was determined.

Results
SEP Price differences ranged from 25.46 to 97.33% between highest- and lowest-priced products and a price variation of 72.09% more for the OB than the LPG medicine, except for one LPG that was more expensive than the OB. Affordability calculations showed that All OB treatments for all three cancers (breast, prostate and colorectal), except for paclitaxel 300 mg (0.2 days wage) and Fluorouracil (Fluroblastin) 500 mg (0.3 days wage) costs respectively were more than 1 day’s wage, with patients diagnosed with colorectal cancer needing 32.5 days wages in order to afford a standard course of treatment for a month.

Conclusion
There was a considerable variation in the price of different brands of cancer medicines available in the South African private sector.
Original languageEnglish
Article number661
Number of pages10
JournalBMC Health Services Research
Volume21
Issue number1
DOIs
Publication statusPublished - 6 Jul 2021

Fingerprint

Dive into the research topics of 'Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa'. Together they form a unique fingerprint.

Cite this